About Peptris
Peptris is a company based in Bengaluru (India) founded in 2019 by Narayanan Venkatasubramanian, Anand Budni, Amit Mahajan, and Shridhar Narayanan. Peptris has raised $9.16 million across 4 funding rounds from investors including Speciale Invest, Anandi Krishnan and Santosh Budni. Peptris offers products and services including AI Drug Discovery Platform, Drug Repurposing Service, and Molecule Rescue Tool. Peptris operates in a competitive market with competitors including Cyrus Biotechnology, Vividion Therapeutics, Seer, Biognosys and ProteinSimple, among others.
- Headquarter Bengaluru, India
- Founders Narayanan Venkatasubramanian, Anand Budni, Amit Mahajan, Shridhar Narayanan
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Peptris Technologies Private Limited
- Date of Incorporation 25 Jun, 2019
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$27.49 K (USD)14380.56as on Mar 31, 2022
-
Net Profit
$1.4 K (USD)2007.89as on Mar 31, 2022
-
EBITDA
-$532.3 (USD)0as on Mar 31, 2022
-
Total Equity Funding
$9.16 M (USD)
in 4 rounds
-
Latest Funding Round
$7.72 M (USD), Series A
Feb 18, 2026
-
Investors
Speciale Invest
& 41 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Peptris
Peptris offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform, Drug Repurposing Service, and Molecule Rescue Tool.
Generates novel molecules using AI for efficient drug development
Repurposes approved drugs for new indications and rare diseases
Identifies new targets for safe clinical molecules not pursued further
Funding Insights of Peptris
Peptris has successfully raised a total of $9.16M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $7.72 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Peptris
Peptris has secured backing from 42 investors, including venture fund and angel investors. Prominent investors backing the company include Speciale Invest, Anandi Krishnan and Santosh Budni.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in deep tech startups with a focus on early-stage innovations in technology and engineering.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Peptris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Peptris
Investment portfolio details for Peptris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Peptris
Detailed financials for Peptris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Peptris Comparisons
Peer comparison for Peptris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Peptris
Peptris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cyrus Biotechnology, Vividion Therapeutics, Seer, Biognosys and ProteinSimple, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud-based protein-modeling software is developed for drug discovery.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
|
| Locked | Locked | Locked |
Small molecule oncology therapeutics are developed for cancer treatment.
|
Detailed competitors of Peptris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Peptris
Complete news archive for Peptris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Peptris
Peptris was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Peptris is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Narayanan Venkatasubramanian is the current CEO of Peptris. They have also founded this company.
Peptris is a funded company, having raised a total of $9.16M across 4 funding rounds to date.
Annual revenue of Peptris is $27.49K as on Mar 31, 2022.
Peptris was founded in 2019 in Bengaluru, India, as a provider of AI-based software for proteomic data analysis in the drug discovery sector. A computational platform has been developed to support the analysis and interpretation of experimental data. Capabilities include predictions of molecular interactions between proteins and identification of target proteins, aiding research operations in biotechnology.
Peptris's top competitors include Vividion Therapeutics, Cyrus Biotechnology and Biognosys.
Peptris offers AI Drug Discovery Platform, Drug Repurposing Service, and Molecule Rescue Tool.
Peptris has 42 investors. Key investors include Speciale Invest, Anandi Krishnan, Santosh Budni, Subhadradevi Leela, and Deepak Mittal.
The valuation of Peptris is $1.61M as of Nov 2021.